Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Schiavino D et al. – The rate of cross–reactivity between imipenem–cilastatin and other beta–lactams was 5.5%. This result is different from previous findings and this may be explained by the fact that authors investigated patients with cell–mediated allergy to beta–lactams. Patients with cell–mediated allergy to beta–lactams should undergo patch tests and a tolerance challenge test before treatment with imipenem–cilastatin.

Related Articles

Epidemiology and Impact of Imipenem Resistance in Acinetobacter baumannii
Infection Control and Hospital Epidemiology, 10/28/09    Relevance Score: 83%

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
Current Medical Research and Opinion, 11/13/09    Relevance Score: 80%

Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates
American Journal of Infection Control, 11/12/09    Relevance Score: 80%

Recurrent cellulitis following buttock augmentation
The Clinical Advisor, 11/09/09    Relevance Score: 77%

Today in Allergy/Immunology...keeping you current

Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins
International Journal of Dermatology, 12/04/09

Slowing Progression Along the Allergic Disease Continuum: Quo Vadit Immunotherapy
Pediatric Asthma, Allergy & Immunology, 12/04/09

IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis
Journal of Clinical Laboratory Analysis, 12/04/09

Today in Clinical Pharmacology...keeping you current

Divalproex Sodium-Induced Eosinophilic Pleural Effusion
American Journal of Therapeutics, 12/04/09

Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09

Acute Generalized Exanthematous Pustulosis: A Rare Clinical Entity With Use of Piperacillin/Tazobactam
American Journal of Therapeutics, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address